Article
Gastroenterology & Hepatology
Tae Hyung Kim, Minkoo Kim, Hyung Joon Yim, Sang Jun Suh, Young Kul Jung, Yeon Seok Seo, Soon Ho Um, Jung Il Lee, Sae Hwan Lee, Sang Gyun Kim, In Hee Kim, Hyoung Su Kim, Eun Young Cho, Tae Yeob Kim, Seong Gyu Hwang
Summary: In the treatment of LMV-resistant CHB, the combination therapy of L-dT and ADV did not demonstrate any clinical benefit over the combination of LMV and ADV.
Article
Medicine, General & Internal
Hailemichael Desalegn, Stian Magnus Staurung Orlien, Hanna Aberra, Eyerusalem Mamo, Sine Grude, Kristina Hommersand, Nega Berhe, Svein Gunnar Gundersen, Asgeir Johannessen
Summary: This pilot program demonstrates the long-term benefits of CHB therapy in a resource-limited setting. The high mortality in patients with cirrhosis underscores the need for earlier detection of CHB and timely initiation of antiviral treatment in sub-Saharan Africa.
Article
Medicine, General & Internal
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Annemarie Berger, Dmitry Manuilov, Vithika Suri, Qi An, Ben Da, John Flaherty, Anu Osinusi, Yang Liu, Uta Merle, Julian Schulzezur Wiesch, Stefan Zeuzem, Sandra Ciesek, Markus Cornberg, Pietro Lampertico
Summary: In this study, it was found that bulevirtide is effective in inhibiting the entry of hepatitis D virus and reducing the progression of liver disease in patients with chronic hepatitis B. The recommended dosage of bulevirtide is 2 mg or 10 mg per day.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Annemarie Berger, Dmitry Manuilov, Vithika Suri, Qi An, Ben Da, John Flaherty, Anu Osinusi, Yang Liu, Uta Merle, Julian Schulze zur Wiesch, Stefan Zeuzem, Sandra Ciesek, Markus Cornberg, Pietro Lampertico
Summary: Bulevirtide treatment reduces HDV RNA and ALT levels in patients with chronic hepatitis D, with a dose-dependent effect.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Sisi Yang, Xueqing Ma, Chengwei Cai, Huanqiu Wang, Fenqiang Xiao, Chengbo Yu
Summary: The study found that TDF is more effective than ETV in reducing HBsAg levels in patients with chronic hepatitis B who have not received nucleoside analog treatment, especially in those with high baseline HBsAg levels (>3 log IU/mL).
FRONTIERS IN MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Lai Wei, Tingting Zhao, Ji Zhang, Qing Mao, Guozhong Gong, Yongtao Sun, Yongping Chen, Maorong Wang, Deming Tan, Zuojiong Gong, Baosen Li, Junqi Niu, Shuchen Li, Huanyu Gong, Liyun Zou, Wei Zhou, Zhengcai Jia, Yan Tang, Lei Fei, Yang Hu, Xiaoyun Shang, Junfeng Han, Bei Zhang, Yuzhang Wu
Summary: The study evaluated the efficacy and safety of epsilon PA-44 in patients with chronic hepatitis B through a two-stage phase 2 trial. Results showed that 900μg epsilon PA-44 significantly increased the HBeAg seroconversion rate and produced sustained off-treatment effect for patients.
Article
Medicine, Research & Experimental
Ya-Hui Huang, Chau-Ting Yeh, Chao-Wei Hsu, Yang-Hsiang Lin
Summary: In this retrospective study, it was found that telbivudine treatment reduced the concentrations of soluble ACE2 (sACE2) in the serum of chronic hepatitis B patients. This suggests that telbivudine may potentially reduce the risk of SARS-CoV-2 infection.
CURRENT MOLECULAR MEDICINE
(2023)
Article
Immunology
Yanhang Gao, Fei Kong, Xinwen Song, Jia Shang, Lvfeng Yao, Jinyu Xia, Yanzhong Peng, Weidong Liu, Huanyu Gong, Mao Mu, Hesong Cui, Tao Han, Wen Chen, Xiaolu Wu, Yongfeng Yang, Xuebing Yan, Zhenjing Jin, Peng Wang, Qingjing Zhu, Liang Chen, Caiyan Zhao, Dengke Zhang, Weili Jin, Daidi Wang, Xiuhong Wen, Chunmei Liu, Jidong Jia, Qing Mao, Yanhua Ding, Xueyuan Jin, Zong Zhang, Qianguo Mao, Guangming Li, Junqi Niu
Summary: In a phase 2 trial, pradefovir showed comparable antiviral activity against HBV and good safety profile to tenofovir disoproxil fumarate. Pradefovir at doses of 30, 45, 60, and 75 mg effectively reduced HBV DNA levels and resulted in more HBeAg loss compared to TDF.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Pharmacology & Pharmacy
Xia Tang, Wenxun Huang, Juan Kang, Keyue Ding
Summary: Telbivudine treatment in chronic HBV patients led to significant differences in viral quasispecies, with a reduced dN/dS ratio indicating selective constraints from antiviral therapy. Evolution patterns and resistant mutations in the quasispecies varied over a short-term treatment course.
ANTIVIRAL RESEARCH
(2021)
Article
Infectious Diseases
Man-Fung Yuen, Rozalina Balabanska, Emmanuelle Cottreel, Ethan Chen, Dan Duan, Qiudi Jiang, Avinash Patil, Miriam Triyatni, Ruchi Upmanyu, Yonghong Zhu, Filippo Canducci, Edward J. Gane
Summary: The safety and tolerability of RO7020531 were assessed in healthy volunteers and patients with chronic hepatitis B virus (HBV) infection. The results showed that RO7020531 demonstrated acceptable safety and tolerability in both healthy volunteers and patients. Therefore, RO7020531 has the potential to be developed for the treatment of chronic HBV infection.
LANCET INFECTIOUS DISEASES
(2023)
Article
Immunology
Milan J. Sonneveld, Bettina E. Hansen, Willem P. Brouwer, Henry L-Y Chan, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Rong-Nan Chien, Robert J. de Knegt, Cynthia Wat, Vedran Pavlovic, Anuj Gaggar, Qing Xie, Maria Buti, Robert A. de Man, Harry L. A. Janssen
Summary: This study investigated the relationship between HBsAg levels and hepatic fibrosis and cirrhosis in patients with chronic hepatitis B. The results showed that lower HBsAg levels were associated with higher rates of fibrosis and cirrhosis in HBeAg-positive patients, but not in HBeAg-negative patients. Additionally, genotype-specific HBsAg cutoffs could be used to rule out the presence of cirrhosis. These findings are important for the diagnosis and treatment of chronic hepatitis B patients.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Gastroenterology & Hepatology
Stanislas Pol
Summary: This study compared the impact of tenofovir and entecavir on outcomes of patients with HBV infection, and found that there was no difference in the incidence rates of HCC, DC, LT, and other liver-related events between the two treatments.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Food Science & Technology
Baofang Zhang, Lei Yu, Mingliang Cheng, Quan Zhang, Jun Wu, Jing Yang, Qin Liu, Shuang Lu, Xueke Zhao, KaiSheng Deng, Yongmei Liu, Jun Wang, Peiling Zhao
Summary: The study showed that HBV genotype had an independent association with HBV DNA change response to telbivudine or tenofovir in pregnant women with hepatitis B. There were significant differences in HBV DNA levels post-treatment between telbivudine and tenofovir groups, despite similar clinical characteristics and liver function tests.
FOOD SCIENCE & NUTRITION
(2022)
Review
Biochemistry & Molecular Biology
Mojisola Ogunnaike, Srijanee Das, Samiksha S. Raut, Ashrafi Sultana, Mohammad Ullah Nayan, Murali Ganesan, Benson J. Edagwa, Natalia A. Osna, Larisa Y. Poluektova
Summary: Chronic hepatitis B virus (HBV) infection can lead to the development of cirrhosis and hepatocellular carcinoma. Lifelong treatment with nucleotides/nucleoside antiviral agents is effective but adherence can be challenging. This review discusses recent advances in the development of long-acting formulations and curative strategies for HBV treatment, highlighting promising antivirals and genome editing approaches.
Article
Pharmacology & Pharmacy
Cuicui Li, Xiaoli Bi
Summary: The clinical study on pregnant women with chronic hepatitis B virus infection found that telbivudine treatment has better efficacy in HBV patients and plays a role in blocking mother-to-child transmission.
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Zobair M. Younossi, Janus P. Ong, Hirokazu Takahashi, Yusuf Yilmaz, Yuichiro Eguc Hi, Mohamed El Kassas, Maria Buti, Moises Diago, Ming-Hua Zheng, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Khalid Alswat, Wah-Kheong Chan, Nahum Mendez-Sanchez, Patrizia Burra, Elisabetta Bugianesi, Ajay K. Duseja, Jacob George, George Papatheodoridis, Hamid Saeed, Laurent Castera, Marco Arrese, Marcelo Kugelmas, Manuel Romero-Gomez, Saleh Alqahtani, Mariam Ziayee, Brian Lam, Issah Younossi, Andrei Racila, Linda Henry, Maria Stepanova
Summary: This study evaluated the knowledge of NAFLD among physicians of different specialties globally, revealing significant differences in knowledge levels among different specialties, with hepatologists and endocrinologists scoring higher than gastroenterologists and primary care physicians.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Alkistis Papatheodoridi, George Papatheodoridis
Summary: Hepatocellular carcinoma (HCC) is a major public health problem and is one of the leading causes of cancer-related deaths worldwide. Hepatitis B (HBV) and C (HCV) viruses have been identified as oncoviruses and are responsible for most cases of HCC, while the role of hepatitis D (HDV) virus in liver cancer development remains unclear. Coinfection of HDV/HBV is associated with more severe liver damage than HBV mono-infection, and recent studies suggest that HDV/HBV patients are at increased risk of developing HCC compared to those with HBV alone. This review summarizes the current literature on the impact of HDV in HCC development and discusses the potential interactions between HBV, HDV, and neighboring liver tissue in liver carcinogenesis.
LIVER INTERNATIONAL
(2023)
Letter
Gastroenterology & Hepatology
Margarita Papatheodoridi, Anna S. Lok, George V. Papatheodoridis
Review
Gastroenterology & Hepatology
Heiner Wedemeyer, Tammo L. Tergast, Jeffrey V. Lazarus, Homie Razavi, Kostas Bakoyannis, Ricardo Baptista-Leite, Marco Bartoli, Philip Bruggmann, Cristian-Silviu Busoi, Maria Buti, Manuel Carballo, Laurent Castera, Massimo Colombo, Rodrigo Sousa Coutinho, Yuval Dadon, Gamal Esmat, Rafael Esteban, Joan Colom Farran, Mark Gillyon-Powell, David Goldberg, Sharon Hutchinson, Harry L. A. Janssen, George Kalamitsis, Loreta A. Kondili, John S. Lambert, Rui Tato Marinho, Mojca Maticic, Aldo Patricello, Markus Peck-Radosavljevic, Stanislas Pol, Mario Poljak, Cora Pop, Tomislov Sokol, Vana Sypsa, Nurdan Tozun, Zobair Younossi, Alessio Aghemo, George V. Papatheodoridis, Angelos Hatzakis
Summary: In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA) launched the HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030. Although progress has been made, most countries are not on track to reach the elimination targets. The COVID-19 pandemic has also hindered efforts, resulting in a decrease in HCV diagnoses and treatment initiations. It is crucial to reinforce action and gain commitment from policymakers to achieve HCV elimination.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Dimitrios S. Karagiannakis, Theodoros Voulgaris, George Markakis, Dimitra Lakiotaki, Elisavet Michailidou, Evangelos Cholongitas, George Papatheodoridis
Summary: This study found that spleen stiffness measurement (SSM) by 2D shear-wave elastography could better predict the probability of liver decompensation and mortality compared to liver stiffness measurement (LSM) and other parameters. SSM showed better diagnostic accuracy for the prediction of 1-year decompensation or death.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Letter
Gastroenterology & Hepatology
George Papatheodoridis, Vasileios Lekakis, Anna S. Lok, K. Rajender Reddy
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Zobair M. Younossi, Ming-Lung Yu, Yusuf Yilmaz, Khalid Aida Alswat, Maria Buti, Marlen Ivon Castellanos Fernandez, Georgios Papatheodoridis, Saeed S. Hamid, Mohamed El-Kassas, Wah Kheong Chan, Ajay K. Duseja, Stuart C. Gordon, Yuichiro Eguchi, Vasily A. Isakov, Stuart K. Roberts, Jian-Gao Fan, Ashwani K. Singal, Manuel Romero-Gomez, Aijaz Ahmed, Janus Ong, Brian P. Lam, Issah Younossi, Fatema Nader, Andrei Racila, Maria Stepanova, Saleh Alqahtani
Summary: Chronic hepatitis B (CHB) infection is a common cause of cirrhosis and liver cancer worldwide. The Global Liver Registry is being used to assess the clinical and patient-reported outcomes (PROs) of CHB patients from different regions. The study included 1818 CHB patients from 15 countries, with varying rates of advanced fibrosis. HBV subjects from the Middle East/North Africa had the lowest PRO scores, while those from Southeast/East and South Asia had the highest. Factors associated with PRO impairment in CHB patients included advanced fibrosis, non-hepatic comorbidities, and female sex.
JOURNAL OF VIRAL HEPATITIS
(2023)
Article
Medicine, General & Internal
Huai Zhang, Rafael S. Rios, Jerome Boursier, Rodolphe Anty, Wah-Kheong Chan, Jacob George, Yusuf Yilmaz, Vincent Wai-Sun Wong, Jiangao Fan, Jean-Francois Dufour, George Papatheodoridis, Li Chen, Joern M. Schattenberg, Junping Shi, Liang Xu, Grace Lai-Hung Wong, Naomi F. Lange, Margarita Papatheodoridi, Yuqiang Mi, Yujie Zhou, Christopher D. Byrne, Giovanni Targher, Gong Feng, Minghua Zheng
Summary: This study aimed to investigate the utility of cytokeratin-18 (CK-18) M30 concentrations as a non-invasive diagnostic tool for non-alcoholic steatohepatitis (NASH). The results showed that there was a difference in CK-18 M30 levels between NASH and non-alcoholic fatty liver (NAFL) patients, but the sensitivity and positive predictive value were not ideal. Therefore, measurement of CK-18 M30 levels alone has limited value for non-invasively diagnosing NASH.
CHINESE MEDICAL JOURNAL
(2023)
Review
Surgery
Evangelos Cholongitas, Patrizia Burra, Georgia Vourli, George V. Papatheodoridis
Summary: The use of initial/early everolimus appears to be effective and has a satisfactory safety profile, making it a reasonable therapeutic option in liver transplantation.
CLINICAL TRANSPLANTATION
(2023)
Article
Pharmacology & Pharmacy
Dimitrios Bampatsias, Maria-Angeliki Dimopoulou, Dimitrios Karagiannakis, Alexandros Sianis, Eleni Korompoki, Kanella Kantreva, Erasmia Psimenou, Georgia Trakada, George Papatheodoridis, Kimon Stamatelopoulos
Summary: This article reports a case of a HoFH patient who experienced a sudden decrease in blood lipid levels during SARS-CoV-2 infection, followed by a rebound increase refractory to treatment. Marker of liver stiffness increased at 9 months and decreased at 18 months after the infection. The potential interactions of hypolipidemic treatment with the viral replication process and the therapeutic dilemmas in the post-infection period are discussed.
JOURNAL OF CLINICAL LIPIDOLOGY
(2023)
Article
Medicine, General & Internal
Anastasia Katsoula, Georgios Axiaris, Afroditi Mpitouli, Maria Palatianou, Angeliki Christidou, Nikolaos Dimitriadis, Andreas Nakos, Ploutarchos Pastras, Panagiotis Kourkoulis, Pantelis Karatzas, Miltiadis Moutzoukis, Charalampos Zlatinoudis, Athanasios Philippidis, Anastasia Kourikou, Georgios Kokkotis, Antonios Gklavas, Angeliki Machaira, Aikaterini Mantaka, Persefoni Talimtzi, Evaggelia Anagnostopoulou, Ioannis E. Koutroubakis, Ioannis Papaconstantinou, Georgios Bamias, Spilios Manolakopoulos, Nicoletta Mathou, Konstantina Paraskeva, Andreas Protopappas, Eftychia Tsironi, Konstantinos H. H. Katsanos, Dimitrios K. K. Christodoulou, Georgios Papatheodoridis, Georgios Michalopoulos, Georgios Theocharis, Christos Triantos, Ioannis Pachiadakis, Konstantinos Soufleris, Nikolaos Viazis, Gerassimos J. Mantzaris, Georgios Tribonias, Maria Tzouvala, Angeliki Theodoropoulou, Konstantinos Karmiris, Evanthia Zampeli, Spyridon Michopoulos, Anna-Bettina Haidich, Olga Giouleme
Summary: The aim of this study was to validate the content of IBD-Disk in a Greek cohort of IBD patients. The results showed good correlation and consistency between the scores of IBD-Disk and IBD-DI at baseline and follow-up. Female gender and extraintestinal manifestations were significantly associated with a higher IBD-Disk total score. Therefore, the Greek version of IBD-Disk was proven to be a reliable and valid tool for assessing IBD-related disability.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Maria Tampaki, George V. Papatheodoridis, Evangelos Cholongitas
Summary: Patients with decompensated hepatocellular carcinoma (HCC) have limited therapeutic options and are often excluded from clinical trials. Liver transplantation is the best treatment option, but strict criteria and donor shortages limit its availability. Locoregional treatments may provide a survival benefit if well tolerated. Systemic treatments, particularly immunotherapy, may be the safest choice based on real-life data. Close monitoring is necessary due to the high risk of liver disease deterioration.
Article
Microbiology
Nikolaos D. D. Karakousis, Lampros Chrysavgis, Alkistis Papatheodoridi, Aigli-Ioanna Legaki, Panagiotis Lembessis, Evangelos Cholongitas, Antonios Chatzigeorgiou, George Papatheodoridis
Summary: This study investigates the levels of circulating cf-DNA and 5-methyl-2'-deoxycytidine in HBeAg-negative patients with chronic hepatitis B (CHB). The results show that circulating cf-DNA concentration significantly increased after treatment initiation. There was also a trend in increasing levels of 5-methyl-2'-deoxycytidine after treatment initiation in CHB patients. These findings suggest that both cf-DNA and 5-methyl-2'-deoxycytidine may serve as useful biomarkers to monitor liver disease activity and response to antiviral treatment in HBeAg-negative chronic HBV patients.
Article
Gastroenterology & Hepatology
Theodoros Voulgaris, Vassileios Lekakis, Jiannis Vlachogiannakos, Dimitrios Kamberoglou, Afroditi Orfanidou, George Papatheodoridis, George Karamanolis
Summary: In this study, we retrospectively assessed the efficacy of citalopram or amitriptyline versus no treatment in patients with functional chest pain (FCP). The results showed that both citalopram and amitriptyline are effective pharmacological options in the symptomatic relief of almost 50% of patients with well characterized FCP.
ANNALS OF GASTROENTEROLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
George V. Papatheodoridis, Konstantinos Mimidis, Spilios Manolakopoulos, Christos U. Triantos, Ioannis Vlachogiannakos, Christos Veretanos, Melanie Deutsch, Stylianos Karatapanis, Ioannis Goulis, Ioannis S. Elefsiniotis, Evangelos Cholongitas, Vasileios Sevastianos, Dimitrios Christodoulou, Dimitrios N. Samonakis, Emanuel Manesis, Andreas Kapatais, Nikolaos Papadopoulos, Panagiota Ioannidou, Georgios Germanidis, George Giannoulis, Dimitra Lakiotaki, Dionysios Kogias, Charikleia Kranidioti, Konstantinos Zisimopoulos, Maria Mela, George Kontos, Paraskevi Fytili, Chrysanthi Manolaka, Polyxeni Agorastou, Spyridon I. Pantzios, Dimitrios Karagiannakis, Eleni Geladari, Nikolaos Psychos, Kalliopi Zachou, Anna Chalkidou, Anastasia Spanoudaki, Konstantinos Thomopoulos, George N. Dalekos